Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.
A clinically meaningful absolute risk reduction in invasive disease-free survival and distant relapse-free survival with abemaciclib plus endocrine therapy was maintained in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer regardless of age.
Findings from the monarchE trial presented at ASCO showed that for patients with hormone receptor–positive, HER2-negative, high-risk, early breast cancer, Verzenio provided “consistent treatment benefit.”